Tumor location may help you identify the right treatment for your mCRC patients.
Review the efficacy results of ERBITUX combination therapy across 3 subgroup post hoc analyses of tumor sidedness in RAS wild-type mCRC
Go to the CRYSTAL, FIRE-3, and CALGB/SWOG 80405 data
CRYSTAL=Cetuximab combined with iRinotecan in first-line therapY for metaSTatic colorectAL cancer
FIRE-3: FOLFIRI + cetuximab versus FOLFIRI + bevacizumab as first-line treatment for patients with mCRC
CALGB=Cancer and Leukemia Group B; SWOG=Southwest Oncology Group.
Metastatic Colorectal Cancer
ERBITUX is indicated for the treatment of KRAS wild-type, epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer (mCRC) as determined by an FDA-approved test for this use:
- In combination with FOLFIRI (irinotecan, fluorouracil, leucovorin) for first-line treatment
- In combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy
- As a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan
Limitations of Use: ERBITUX is not indicated for treatment of RAS-mutant colorectal cancer or when the results of the RAS mutation tests are unknown.